tigger transposable element derived 6Genealiases: []
Q-omics provides the consensus-scored TIGD6 profile across patient tissues and cancer cell-line models. TIGD6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TIGD6 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, TIGD6 RNA expression shows 19,446 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, HNSC, and UVM as cancer lineages where TIGD6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TIGD6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TIGD6 survival associations across molecular data types. TIGD6 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TIGD6 RNA expression–survival associations across cancer types. High TIGD6 expression shows unfavorable associations in KICH, STAD and LIHC, but favorable associations in MESO, READ and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TIGD6 RNA expression.
This table summarizes TIGD6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TIGD6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TIGD6 shows higher tumor expression in HNSC, LIHC, CHOL, KIRP, LUAD and KIRC. The HNSC box plot shows higher TIGD6 RNA expression in tumor versus normal tissue (log2 FC = +0.412, t-test p < 0.001).
This table shows molecular features associated with TIGD6 in patient tissues and cancer cell lines. In patient samples, TIGD6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TIGD6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
